The startup develops a medical device that filters circulating tumor cells from a patient's bloodstream, aiming to slow cancer metastasis. This technology provides critical insights into cancer spread, enabling targeted therapeutic interventions for metastatic cancer.
Funding
$15.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Metastatic cancer, the spread of cancer cells to distant sites, is a leading cause of cancer-related deaths. Current methods for monitoring and analyzing circulating tumor cells (CTCs) in the bloodstream are often invasive, time-consuming, and lack the sensitivity needed for early detection of metastasis.
Solution
This startup is developing a medical device designed to selectively capture and analyze circulating tumor cells (CTCs) directly from a patient's bloodstream. The device uses a microfluidic platform to efficiently filter and isolate CTCs, providing a non-invasive method for monitoring cancer progression and treatment response. By analyzing the captured CTCs, clinicians can gain valuable insights into the molecular characteristics of the tumor, identify potential drug targets, and personalize treatment strategies. The technology aims to improve the management of metastatic cancer by enabling earlier detection, more precise monitoring, and targeted therapeutic interventions.
Target Audience
The primary target audience includes oncologists, pathologists, and researchers involved in cancer diagnostics, treatment monitoring, and drug development.
Features
- Microfluidic chip for high-throughput capture of CTCs from whole blood samples
- Non-invasive blood draw procedure, minimizing patient discomfort
- High sensitivity and specificity for CTC isolation, even at low concentrations
- Downstream analysis capabilities, including single-cell sequencing and proteomic profiling
- Automated data analysis and reporting software for streamlined interpretation of results